Sanketkumar Nehul

This study identifies efavirenz's anti-CHIKV activity and shows it inhibits viral replication by targeting minus-sense RNA synthesis, suggesting its repurposing for antiviral therapy.

This study identifies a new molecular interaction between G3BP1 and SARS-CoV-2 N protein and shows small molecules disrupt this interaction, reducing viral replication.

This paper develops an in silico affinity maturation pipeline to enhance nanobody binding to the SARS-CoV-2 Omicron RBD, achieving three-fold improved affinity through computational and experimental validation.

This study enhances the affinity of SARS-CoV-2 neutralizing nanobodies through structure-guided mutations in CDRs, resulting in improved neutralization activity against pseudovirus.

This study evaluates the antiviral and anti-inflammatory effects of triterpenoids against SARS-CoV-2 by targeting viral proteases and host immune pathways.

This study identifies antivirals targeting multiple sites of SARS-CoV-2 RdRp complex through in-silico screening, SPR validation, and cell-based assays, showing potent antiviral effects.

This study develops a bivalent chimeric virus-like particle vaccine displaying CHIKV and SARS-CoV-2 RBD antigens, showing potent immunogenicity in mice.

This study identifies DUB inhibitors that target SARS-CoV-2 PLpro, inhibiting its proteolytic activity and restoring immune responses in a mouse model.